Obesity| New Atlas
The US has officially got a homegrown hero in the burgeoning global industry of effective weight-loss treatments, with the FDA approval of Eli Lilly’s Zepbound. The company has announced the once-a-week injectable drug's cost, dosages, insurance subsidies and when it will be on shelves.| New Atlas
The race is on to develop the first daily weight-loss pill that would be both cheaper and less invasive than the current injectable drugs on the market, with the latest strong trial results from US company Terns following similarly positive outcomes from competitors including Eli Lilly, Roche and…| New Atlas
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.| Eli Lilly and Company
